Any current/future new fundraising through debt or equity?

There is no explicit mention of any new fundraising through debt in the call transcript. Dr. Rohit Madhav Sane mentioned preferential share allotment subscription for himself expected to finalize within a month, with a dilution of less than 5%. The preferential allotment funds might be used for capex related to hospital bed additions, especially at Khopoli hospital. No other specific equity or debt fundraising plans were disclosed for current or future periods. The company appears to focus on internal accruals and conservative revenue guidance for growth and CAPEX.

Future growth expectations in sales/revenue/volumes?

Conservative revenue guidance for FY25: around Rs. 97 to 100 crores, similar to last year’s turnover. EBITDA margins expected to sustain or improve due to cost efficiencies (HR cost reduction, professional fees optimization, and controlled COGS). Expansion plans for hospitals include adding 40-60 beds each at Khopoli and Kondhali hospitals within 12-18 months. Long-term vision to add 10 more hospitals, focusing on acquisitions and franchise-like expansions, especially in North India, Gujarat, and South India. Plans to establish about 1,000 clinics, 10 hospitals, and 5,000 outpatient de

Any current/future capex/capital investment/strategic investment?

Khopoli hospital: Plans to add 80 more beds on adjacent land over 12-18 months, in phases of 20-40 beds; estimated cost Rs. 8-10 crores. Awaiting government permissions (~1 month). Nagpur hospital: Planning an addition of 20 beds in next 12-18 months. Expansion focus on acquiring existing hospitals or resorts and converting them into Madhavbaug facilities through a franchise-like model, targeting North India, Gujarat, and South India. Future plan includes adding 40 to 60 beds in Khopoli and Kondhali hospitals within the next 12-18 months. Expansion being funded through preferential allotment a

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a conservative revenue of around Rs. 97-100 crores for the full year FY25, similar to last year’s turnover. EBITDA margins are expected to sustain and potentially improve beyond current levels due to optimized HR costs, reduced COGS (22-24%), and controlled professional fees. PAT is projected to rise significantly, with a potential increase from Rs. 2.3 crores (last year) to Rs. 7-8 crores for the full year. EBITDA margin improvement is anticipated as topline grows since fixed costs like HR and professional fees won't increase proportionally. A 700% profit jump is forecaste

Vaidya Sane Ayurved Laboratories LtdQ2 FY25Healthcare Equipment & Supplies

Vaidya Sane Ayurved Laboratories Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹136P/E: 15.9Market Cap: ₹143 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 4

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Conservative revenue guidance for FY25: around Rs. 97 to 100 crores, similar to last year’s turnover.
EBITDA margins expected to sustain or improve due to cost efficiencies (HR cost reduction, professional fees optimization, and controlled COGS).
Expansion plans for hospitals include adding 40-60 beds each at Khopoli and Kondhali hospitals within 12-18 months.
Long-term vision to add 10 more hospitals, focusing on acquisitions and franchise-like expansions, especially in North India, Gujarat, and South India.
Plans to establish about 1,000 clinics, 10 hospitals, and 5,000 outpatient departments by 2030, targeting rural areas.
FMCG (Madhavprash) expected to grow gradually with marketing ramp-up and increased retail inquiries.
Marketing efforts are being optimized, with a strong focus on treatment-first approach to drive patient volume growth.
Potential patient surge anticipated with Ayushman Bharat's Ayurvedic coverage, supported by expanding infrastructure and NABH accreditation.

Margin guidance

Category 1

The company expects a conservative revenue of around Rs. 97-100 crores for the full year FY25, similar to last year’s turnover.
EBITDA margins are expected to sustain and potentially improve beyond current levels due to optimized HR costs, reduced COGS (22-24%), and controlled professional fees.
PAT is projected to rise significantly, with a potential increase from Rs. 2.3 crores (last year) to Rs. 7-8 crores for the full year.
EBITDA margin improvement is anticipated as topline grows since fixed costs like HR and professional fees won't increase proportionally.
A 700% profit jump is forecasted for the full year compared to the previous year.
Expansion plans include adding 40-60 beds in existing hospitals within 12-18 months, aiming for growth primarily in hospital business due to higher margins.
FMCG business growth is gradual, focusing on increasing sales of products like Madhavprash, with marketing plans to scale up sales in the near term.

See what Vaidya Sane Ayurved Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any new fundraising through debt in the call transcript.
Dr. Rohit Madhav Sane mentioned preferential share allotment subscription for himself expected to finalize within a month, with a dilution of less than 5%.
The preferential allotment funds might be used for capex related to hospital bed additions, especially at Khopoli hospital.
No other specific equity or debt fundraising plans were disclosed for current or future periods.
The company appears to focus on internal accruals and conservative revenue guidance for growth and CAPEX.

Order book

The transcript does not explicitly mention details about the current or expected order book or any pending orders for Vaidya Sane Ayurved Laboratories Limited. However, some relevant points related to business growth and operations are: - The company is focused on expanding hospital beds by 40 to 60 beds over the next 12 to 18 months. - Plans to increase hospital infrastructure specifically in Khopoli and Kondhali hospitals. - Franchise hospital model discussions are ongoing, indicating future expansion possibilities. - Clinics utilization currently at 45-50% capacity with potential to accommodate 3 times more patients. - Marketing campaigns are being optimized to increase patient inflow and revenues. - EBITDA margins expected to improve with increasing topline. - FMCG business (Madhavprash) sales showing growth potential with online sales expanding. There is no detailed mention of quantifiable order book or pending order values in the call.

See what Vaidya Sane Ayurved Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Khopoli hospital: Plans to add 80 more beds on adjacent land over 12-18 months, in phases of 20-40 beds; estimated cost Rs. 8-10 crores. Awaiting government permissions (~1 month).
Nagpur hospital: Planning an addition of 20 beds in next 12-18 months.
Expansion focus on acquiring existing hospitals or resorts and converting them into Madhavbaug facilities through a franchise-like model, targeting North India, Gujarat, and South India.
Future plan includes adding 40 to 60 beds in Khopoli and Kondhali hospitals within the next 12-18 months.
Expansion being funded through preferential allotment and internal accruals.
No immediate new hospital openings planned for 6-8 months; focus on consolidating existing hospital capacity and marketing.
Long-term vision: Add 10 hospitals and about 1,000 clinics by 2030 with emphasis on rural areas.

Track Vaidya Sane Ayurved Laboratories Ltd — get its next earnings analysis in your feed

How does Vaidya Sane Ayurved Laboratories Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisVaidya Sane Ayurved Laboratories Ltd

Rev 4Mar 1

See where Vaidya Sane Ayurved Laboratories Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Vaidya Sane Ayurved Laboratories Ltd rank in Healthcare Equipment & Supplies?

Compare Vaidya Sane Ayurved Laboratories Ltd against every Healthcare Equipment & Supplies company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Vaidya Sane Ayurved Laboratories Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec

Compare:vs Poly Medicure Ltd vs Molbio Diagnosti vs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →